HCV Archives – Page 5 of 29 – Treatment Action Group

Submission to the Office of the High Commissioner for Human Rights Input to HRC resolution 47/17

February 15, 2022
Dorrit Walsh

On February 9, TAG submitted this testimony to the Office of the High Commission for Human Rights (OHCHR) to inform its upcoming report to the Human Rights Council (HRC) on 'human rights in the context of HIV/AIDS' (HRC resolution 47/17).

Promoting Interventions for Viral Hepatitis and Harm Reduction in COP 2022

February 3, 2022
Dorrit Walsh

On February 3, 2022, TAG in collaboration with the International Network of People who Use Drugs (INPUD), Harm Reduction International (HRI), and the World Hepatitis Alliance (WHA), hosted this free webinar.

2021 TAG Update

December 16, 2021
Dorrit Walsh

As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies

November 4, 2021
Dorrit Walsh

On November 4, 2021, Treatment Action Group and the International Treatment Preparedness Coalition presented this webinar outlining the main findings of the upcoming report "Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends."

Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

November 4, 2021
Dorrit Walsh

This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.

cover of october 2021 TAGline - title is "delivering on the promise of long-acting formulations, and the image shows many calendar sheets with the names of months to indicate that these are long-acting technologies

TAGline October 2021

October 7, 2021
Dorrit Walsh

Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.

A Partnership to Expand Access to Lifesaving Testing and Treatment for Hepatitis C

September 20, 2021
Dorrit Walsh

Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.

Have a Heart, Save My Liver! Who Has Access to the Cure in Africa?

September 11, 2021
Dorrit Walsh

On September 11 2021, Treatment Action Group’s Joelle Dountio Ofinboudem presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. The presentation titled, “Have a Heart, Save My Liver! Who Has Access to the Cure in Africa,” explains that accelerating treatment uptake across Africa is urgently needed to meet WHO hepatitis C targets by 2030.

Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing

August 27, 2021
Dorrit Walsh

TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.

Long-Acting Technologies Resource Compendium

July 28, 2021
Dorrit Walsh

Our resource compendium is a non-exhaustive list of materials covering long-acting technologies to inform the hepatitis C, latent tuberculosis infection, and malaria scope of work under the LONGEVITY Project. Long-Acting Technologies Trials Tracker Illustrated Glossary for Long-Acting Technologies Select Scientific…